Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health (NYSE: EVH) will announce its fourth quarter and full year 2020 operating results on February 25, 2021, after market close. A conference call will follow at 5:00 p.m. Eastern Time, where shareholders and participants can dial in to listen. The company offers clinical and administrative solutions to improve health care efficiency. Evolent has received the National Committee for Quality Assurance's Population Health Program Accreditation and is recognized as a leading workplace in health care.
Evolent Health (NYSE: EVH) announced the appointment of Kim A. Keck to its Board of Directors, effective immediately. Keck, with over 30 years of health care experience, replaces retiring board member Bruce Felt. As President and CEO of the Blue Cross Blue Shield Association, she brings valuable insights to Evolent during a critical growth phase. The company also named Cheryl Scott as Lead Independent Director. Evolent aims to enhance its clinical and administrative solutions while maximizing shareholder value.
Evolent Health (NYSE: EVH) has announced a definitive agreement with Bright HealthCare to acquire True Health New Mexico, a wholly-owned subsidiary of Evolent. The transaction, expected to close in the first half of 2021, aims to enhance Evolent's operational framework, while continuing to provide health plan support to True Health New Mexico. Evolent's CEO, Seth Blackley, highlighted the focus on creating shareholder value through organic revenue growth and margin expansion. Current employees of True Health New Mexico will join Bright HealthCare, ensuring continuity in market operations.
Evolent Health (NYSE: EVH) announced a Cooperation Agreement with Engaged Capital, appointing Craig Barbarosh to its Board of Directors as a Class III director. A Strategy Committee will be created to enhance operational efficiency and financial performance. Evolent also plans to amend its Charter to declassify the Board, allowing directors to stand for one-year terms post-2021 Annual Meeting. Engaged Capital emphasizes its commitment to maximizing shareholder value. This move aims to strengthen governance and strategic direction for Evolent's future.
Evolent Health (NYSE: EVH) announced participation in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021. CEO Seth Blackley and CFO John Johnson will present virtually at 9:10 a.m. ET. A live audio-only webcast will be accessible via Evolent's investor relations page.
Evolent Health provides clinical and administrative solutions that enhance health care efficiency and affordability, serving leading payers and providers nationwide. The company has received national recognition for its population health programs and work environment.
Evolent Health, a leading health care solutions provider, announced that CEO Seth Blackley and CFO John Johnson will participate in 1x1 meetings at the 32nd Annual Piper Sandler Healthcare Conference on December 2, 2020. Meetings can be arranged through Piper Sandler. Evolent focuses on improving health care affordability and delivery with a range of services, including total cost of care management. The company has received national recognition for its innovative approach and workplace environment.
Summary not available.
Evolent Health (NYSE: EVH) has partnered with Florida Blue Medicare to provide comprehensive oncology specialty management services through its subsidiary, New Century Health. This collaboration aims to manage the cost and quality of oncology care for 125,000 Medicare Advantage members across Florida's network of 1,000 physicians in 67 counties. The initiative focuses on evidence-based clinical pathways and aligned payment models to enhance patient outcomes and reduce costs. Full health plan operations are set to begin on January 1, 2021.
Evolent Health (NYSE: EVH) reported its Q3 2020 results with a revenue of $264.6 million, marking a 20.2% year-over-year increase. Despite the revenue growth, the company faced a net loss of $(37.3) million. Adjusted EBITDA improved to $12.7 million from $3.3 million in Q3 2019. The company announced new partnerships and completed the Passport Health Plan asset sale, enhancing operational efficiencies. Evolent has a cash position of $387 million as of September 30, 2020, and aims to optimize capital allocation for long-term shareholder value.
Evolent Health (NYSE: EVH) will release its third quarter 2020 operating results on November 5, 2020, after market close. Following the release, a conference call will be held at 5:00 p.m. Eastern Time. Investors can join the call by dialing 855.940.9467 or 412.317.6034 for international participants. The call will include details about Evolent's clinical and administrative solutions aimed at enhancing health care affordability and quality. An audio replay will be available on Evolent's investor relations website for one week post-call.